13th Feb 2019 12:20
LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Wednesday said new data supports the use of Clever-1 antibodies in re-activating an immune response to tumours.
Shares in Faron were up 5.1% at 62.00 pence on Wednesday.
This is positive news for Faron's immunotherapy cancer drug Clevengen, an antibody that neutralises Clever-1 receptors.
Clever-1 promotes tumour growth and prevents the immune system from attacking tumour cells, and so the use of antibodies to block the action of Clever-1 is expected to re-activate an immune response.
Clever-1 antibodies were investigated in multiple mouse cancer models and this was shown to be the case, with Clever-1 antibodies leading to the significant activation of the immune system and "impairment of solid tumour growth".
"We are very pleased about these published results by Faron's scientific network," said Faron Chief Executive Markku Jalkanen.
"We hope to see supportive biomarker changes in our Matins trial patients during the first half of 2019 while we advance development of Clevegen as a novel therapy for patients with currently untreatable solid cancers," Jalkanen added.
The combination of Clever-1 antibodies with PD-1 checkpoint inhibitions was also shown to have a "synergistic anti-tumour benefit".
Faron has filed a new patent application for the combined used of Clevengen and immunotherapy checkpoint inhibitors as a cancer treatment.
Related Shares:
Faron Pharmaceuticals